Implication of receptor activator of NF-κB ligand in Wnt/β-catenin pathway promoting osteoblast-like cell differentiation

Abstract

Recent studies showed that activation of Wnt/β-catenin pathway promoted the differentiation of osteoblast-like cells in the arterial calcification, but its mechanism remains unknown. In this study, the hypothesis that Wnt/β-catenin pathway promotes the differentiation of osteoblast-like cells by upregulating the expression of receptor activator of NF-κB ligand (RANKL) was examined. LiCl was used to activate the Wnt/β-catenin pathway. The differentiation of osteoblast-like cells was observed by Von Kossa staining, calcium content assay, alkaline phosphatase (ALP) activity assay, and detection of osteocalcin expression. Real-time PCR was performed to detect the expression of RANKL and osteoprotegerin (OPG, the decoy receptor of RANKL) during the osteoblast-like cell differentiation. Different concentrations of OPG were added to the culture media respectively to inhibit the function of RANKL, and the change in the differentiation of osteoblast-like cells was evaluated. The results showed that when the Wnt/β-catenin pathway was activated by LiCl, the expression of RANKL was significantly increased, which coincided with the differentiation of osteoblast-like cells (P<0.05), and the OPG treatment could partly attenuate the promoting effect of Wnt/β-catenin pathway on the differentiation of osteoblast-like cells (P<0.05), but it failed to completely abolish such effect. It was concluded that activation of Wnt/β-catenin pathway promotes the differentiation of osteoblast-like cells by both RANKL-dependent and RANKL-independent mechanisms.

Keywords

arterial calcification / Wnt/β-catenin pathway / osteoblast-like cell / osteoprotegerin

References

[1] RennenbergR.J., SchurgersL.J., KroonA.A., et al.. Arterial calcifications. J Cell Mol Med, 2010, 14(9): 2203-2210

[2] NevenE., De SchutterT.M., De BroeM.E., et al.. Cell biological and physicochemical aspects of arterial calcification. Kidney Int, 2011, 79(11): 1166-1177

[3] DellegrottaglieS., SanzJ., RajagopalanS.. Molecular determinants of vascular calcification: a bench to bedside view. Curr Mol Med, 2006, 6(5): 515-524

[4] AbedinM., TintutY., DemerL.L.. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol, 2004, 24(7): 1161-1170

[5] TsushimaM.. Aortic calcification and calcium. Clin Calcium, 2010, 20(11): 1627-1635

[6] TysonK.L., ReynoldsJ.L., McNairR., et al.. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol, 2003, 23(3): 489-494

[7] ShaoJ.S., CaiJ., TowlerD.A.. Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler Thromb Vasc Biol, 2006, 26(7): 1423-1430

[8] BeazleyK.E., DeaseyS., LimaF., et al.. Transglutaminase 2-mediated activation of β-catenin signaling has a critical role in Warfarin-induced vascular calcification. Arterioscler Thromb Vasc Biol, 2012, 32(1): 123-130

[9] ShaoJ.S., ChengS.L., PingsterhausJ.M., et al.. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest, 2005, 115(5): 1210-1220

[10] Al-AlyZ., ShaoJ.S., LaiC.F., et al.. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/-mice. Arterioscler Thromb Vasc Biol, 2007, 27(12): 2589-2596

[11] ChengS.L., ShaoJ.S., HalsteadL.R., et al.. Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis. Circ Res, 2010, 107(2): 271-282

[12] Collin-OsdobyP.. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res, 2004, 95(11): 1046-1057

[13] OsakoM.K., NakagamiH., KoibuchiN., et al.. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ Res, 2010, 107(4): 466-475

[14] PanizoS., CardusA., EncinasM., et al.. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res, 2009, 104(9): 1041-1048

[15] SchoppetM., KavurmaM.M., HofbauerL.C., et al.. Crystallizing nanoparticles derived from vascular smooth muscle cells contain the calcification inhibitor osteoprotegerin. Biochem Biophys Res Commun, 2011, 407(1): 103-107

[16] Di BartoloB.A., SchoppetM., MattarM.Z., et al.. Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. Cardiovasc Res, 2011, 91(3): 537-545

[17] CastellotJ.J., FavreauL.V., KarnovskyM.J., et al.. Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet endoglycosidase. J Biol Chem, 1982, 257(19): 11 256-11 260

[18] OlesenP., NguyenK., WogensenL., et al.. Calcification of human vascular smooth muscle cells: associations with osteoprotegerin expression and acceleration by high-dose insulin. Am J Physiol Heart Circ Physiol, 2007, 292(2): H1058-H1064

[19] HeoJ.S., LeeS.Y., LeeJ.C.. Wnt/β-catenin signaling enhances osteoblastogenic differentiation from human periodontal ligament fibroblasts. Mol Cells, 2010, 30(5): 449-454

[20] VattikutiR., TowlerD.A.. Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol Endocrinol Metab, 2004, 286(5): E686-E696

[21] HelasS., GoettschC., SchoppetM., et al.. Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol, 2009, 175(2): 473-478

[22] XieH., XieP.L., WuX.P., et al.. Omentin-1 attenuates arterial calcification and bone loss in osteoprotegerin-deficient mice by inhibition of RANKL expression. Cardiovasc Res, 2011, 92(2): 296-306

[23] KadenJ.J., BickelhauptS., GrobholzR., et al.. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol, 2004, 36(1): 57-66